News · Heart & Metabolic
A newer drug slowed kidney decline in people whose damage came from blood pressure, not diabetes
Kidney trials are built around diabetes, so the second-largest group has been treated on borrowed evidence. Within a trial of 1,584 patients, the 459 with blood-pressure-driven damage were examined on their own.
- Kidney function declined more slowly on the drug than on placebo.
- Serious kidney and heart events were about 39% less common.
- These patients had kidney damage from high blood pressure, not diabetes.
- That group is usually treated on evidence borrowed from diabetes trials.
- 459 patients within a larger trial, so the numbers are modest.
Diabetes has dominated kidney research for twenty years, for the good reason that it causes more kidney failure than anything else. The consequence is that almost every major trial recruited people with diabetes, and the drugs that emerged were licensed and studied in them.
High blood pressure is the other main route into kidney failure, and the people who get there by that road have been treated largely on inference. What works in diabetic kidney disease is assumed to work in theirs.
Writing in the European Heart Journal, researchers looked at that group directly. Of 1584 randomized participants, 459 had hypertensive nephropathy, and they were examined on their own. Previously this group had been treated on evidence gathered in people with diabetes.
What happened to their kidneys
Kidney function is tracked by the estimated filtration rate, which falls as the organ scars.
Finerenone slowed total eGFR decline against placebo by about 0.65 units per year.
That sounds negligible and is not, because of how the arithmetic of kidney disease works. Function declines gradually over decades until it crosses the threshold where dialysis or transplant becomes necessary. Slowing the annual rate by a small amount moves that crossing point years later, and years of not being on dialysis is the outcome patients care about.
The harder endpoint
Rate-of-decline results are useful and they are markers. The composite of serious kidney and cardiovascular events is the one that counts things happening to people.
It fell by roughly 39%.
That is a substantial figure, and its range stops just short of no effect at the upper end, which is the signature of a result that is real if the subgroup is trustworthy and fragile if it is not.
Why the caveat about subgroups is not a formality
Four hundred and fifty-nine patients within a trial of 1,584 is a slice, and slices behave badly.
A trial contains many subgroups. Some of them will show effects by chance, and the ones that do are the ones that get written up. Both headline numbers here sit just inside the conventional threshold, with intervals that graze no effect.
What tempers it is coherence. Both endpoints moved in the same direction, the effect matches how the drug is understood to work, and the analysis reports the effects as consistent regardless of baseline characteristics rather than appearing only in one corner.
That is the pattern of a real if modest effect. It is not the pattern of a fluke, which usually shows up in one endpoint and vanishes in the others.
What the drug does
Finerenone blocks the mineralocorticoid receptor, the target of aldosterone, a hormone that raises blood pressure and drives scarring in the kidney.
Older drugs in that family exist and are cheap, and they cause potassium to accumulate, which in a failing kidney can be dangerous. Finerenone is more selective, which is the argument for using it in exactly this population.
The patients here were not mildly affected: average filtration was 44 units, roughly a third of normal, with substantial protein leaking into the urine.
Why it matters who was studied
Chronic kidney disease means your kidneys are damaged and cannot filter blood the way they should, and it is largely silent until late.
The population reaching kidney failure through high blood pressure is not a footnote. It is disproportionately older, and in the US disproportionately Black, and it has been the beneficiary of research designed around somebody else’s disease.
A result specific to that group, even a fragile one from a subgroup, is worth more than another confirmation in the population that already has the evidence.
People also ask
What did the analysis find?
In participants with hypertensive nephropathy, finerenone slowed total eGFR decline versus placebo by 0.65 mL/min/1.73 m2 per year (95% CI 0.02-1.29; P = .044) and was associated with a reduction in the composite kidney-cardiovascular outcome (hazard ratio 0.61; 95% CI 0.38-0.99; P = .045).
What is hypertensive nephropathy?
Kidney damage caused by long-standing high blood pressure. The pressure injures the small filtering vessels over years, and it is one of the two leading routes into kidney failure alongside diabetes.
Why does the group matter?
Because the major kidney trials of recent years recruited people with diabetes, so the evidence base for everyone else is thinner. Guidelines extend those findings by analogy rather than by direct test.
How much is 0.65 units of kidney function a year?
Modest annually and cumulative. Kidney function declines over decades, so a small difference in the yearly rate compounds into a meaningful gap in when someone reaches dialysis.
How solid is a subgroup result?
Less solid than a main trial result. Both figures here have intervals that only just clear no effect, which is what a subgroup of 459 within a trial of 1,584 tends to produce.
What is finerenone?
A mineralocorticoid receptor antagonist, blocking a hormone pathway that drives blood pressure and scarring in the kidney. It is a newer, more selective member of an old drug family.
Should a patient ask about it?
Anyone with chronic kidney disease not caused by diabetes could reasonably ask what the evidence supports for them. Prescribing decisions rest with a kidney specialist. This is general information rather than medical advice.